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A 35-year-old woman with acute otitis media was treated 
with amoxicillin 1 g every 8 hours for 8 days. Treatment was 
switched to amoxicillin–clavulanate potassium 875/125 mg 
every 8 hours for 4 days because of lack of response. When 
the patient finished the course of antibiotics, she experienced 
general malaise, nausea, dark urine, and acholia. Physical 
examination revealed jaundice. The patient denied any history 
of alcohol intake, recreational drugs, and other medication 
(prescription, over-the-counter, or herbal preparations). She 
had no known drug allergies or underlying diseases.
Laboratory blood tests showed increased levels of 
aspartate aminotransferase (AST) 1798 IU/mL, alanine 
aminotransferase (ALT, 2130 IU/mL), alkaline phosphatase 
(ALP, 132 IU/L), γ-glutamyl transpeptidase (GGT) 118 IU/L, 
total bilirubin (6.31 mg/dL), and direct bilirubin (1.31 mg/
dL). The leukocyte count was normal, with no eosinophilia, 
and no abnormalities were detected for glucose levels, 
thyroid hormones, protein profile, and prothrombin index. 
The antinuclear antibody (ANA) titer reached 1/320, and 
the anti–smooth muscle antibody (anti-SMA) and anti-liver 
kidney microsome antibody (anti-LKM) titers were negative. 
Serological tests for hepatotropic viruses (IgM anti-HAV, 
HBsAg, IgM anti-HBc, anti-HCV, HCV RNA) and anti-HIV 
antibodies were negative. Abdominal ultrasound indicated 
a normal liver with normal biliary tract. The episode was 
attributed to amoxicillin–clavulanate potassium. The causality 
score was 7 (probable) according to the updated scale of the 
Roussel Uclaf Causality Assessment Method (RUCAM/
CIOMS) [1].
The patient recovered completely 3 weeks after stopping 
treatment, and values for liver function returned to normal.
Thirteen years earlier, the patient had experienced a 
similar episode with general jaundice and laboratory blood 
tests showing an increase in AST (1873 IU/mL), total 
bilirubin (8.82 mg/dL), and an international normalized ratio 
of 2.09. On that occasion, the patient was admitted to hospital 
because of severe liver impairment. The ANA titer reached 
1/160, with negative anti-SMA and anti-LKM titers. Other 
causes of liver injury were excluded: results for IgM anti-
HAV, IgM anti-HBc, anti-HCV, HCV RNA, IgM CMV, and 
IgM EB were negative, and findings for thyroid hormones 
and protein profile were normal. The results of the ultrasound 
examination were normal. The score on the RUCAM/CIOMS 
scale was 7. The patient was diagnosed with acute hepatitis 
of unknown etiology.
On that occasion, the only treatment involved was 
cetirizine 10 mg. The patient had started treatment with this 
antihistamine a month earlier owing to seasonal allergic 
rhinoconjunctivitis. Cetirizine was withdrawn when she was 
admitted to hospital. Her progress was good, and laboratory 
results returned to normal at 6 weeks. The only medication she 
reported having taken between the 2 episodes was naproxen 
(very sporadically).
Based on the findings and the RUCAM/CIOMS scale, the 
patient was diagnosed with drug-induced liver injury (DILI), 
probably secondary to amoxicillin–clavulanate potassium 
and cetirizine.
The laboratory results for the 2 DILI episodes can be seen 
in the Table.
Table. Liver Vest Values in the 2 Episodes of DILI
   DILI 1      DILI 2 
   2004                   2017   2018 
 Jun 12th  Jun 16th  Jul 12th  Jul 30th  Oct 4th  Jul 3rd  Jul 5th  Aug 7th  May 3rd  Jul 10th
ALT (N≤34 IU/L) 1873 1560 90 30 16 342 2130 34 15 15
AST (N≤30 IU/L) 1500 1260 57 28 10 162 1798 31 10 9
TBL (N≤1 mg/dL) 8.8 18.6 2.4 0.8 0.7 1.7 6.3 1.1 0.7 0.7
GGT (N≤26 IU/L) 64 72 78 18 15 152 118 53 15 13
ALF (N≤104 IU/L) 120 120 96 65 62 114 132 66 62 60
INR  (N ≤ 1.2) 2.0 1.7 1.2 0.9 0.9 1 1 1.1 0.9 0.9
Abbreviations: ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; DILI, drug-induced liver injury; 
GGT, γ-glutamyl transpeptidase; INR, international normalized ratio.
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Liver injury has several causes (eg, infections, toxic 
substances, autoimmunity, and drugs). DILI is considered 
when a possible culprit drug is present and other causes of 
liver injury have been excluded. This diagnosis is confirmed 
based on 1 of the following 3 criteria: (1) ALT ≥5 times the 
upper limit of normal (ULN), (2) ALP ≥2 times ULN, (3) ALT 
≥3 times ULN plus total bilirubin ≥2 times ULN [2].
Although hepatotoxicity has been described with 
virtually all drugs, DILI represents fewer than 1% of cases 
of acute liver injury. An incidence of 13.9 to 19.1 cases 
per 100 000 inhabitants has been reported [3]. In a broad review 
of published series of DILI, the authors found that 34.2% 
of cases of suspected DILI had alternative causes of liver 
injury that confounded the DILI diagnosis and suggest that a 
diagnosis of DILI should be established using a score system 
such as the RUCAM/CIOMS scale [4]. Although this scale 
has its limitations, it can sometimes help establish causality in 
DILI. In the case we report, other causes of liver injury were 
excluded, and the RUCAM/CIOMS scale indicated probable 
causality in both episodes.
Susceptibility to DILI is believed to result from interplay 
of multiple factors, including the structure of the drug, the 
patient’s genetic background, the influence of underlying 
diseases, and associated medications [5]. Nevertheless, a 
genetic basis for DILI has not been determined [6].
In the present case, taking into the account the positive 
ANA results in both episodes, we suspect the possible 
involvement of an autoimmune mechanism not yet clarified. 
Lucena et al [7] reviewed all registered cases of DILI in Spain 
over a period of 15 years and found that the frequency of 
individuals experiencing 2 DILI episodes caused by different 
drugs was 1.21%. Researchers found that second episodes 
of DILI were more likely to be associated with features of 
autoimmune hepatitis; however, it remained uncertain whether 
this was drug-induced unmasking of true autoimmune hepatitis 
or DILI with an autoimmune component. In addition, the drugs 
were not related in structure or function in only 2 patients, as 
occurred in the case we report here: the patient first had DILI 
due to cetirizine and then a second episode of DILI a few years 
later due to amoxicillin–clavulanate potassium. According to 
the US DILI Network [8] and other publications [3], DILI 
is mainly caused by antimicrobial agents, with amoxicillin-
clavulanate being the most prominent one [8]. Of note, 
amoxicillin without clavulanate does not appear in the 
top 10 major individual agents causing DILI [9]. However, 
fewer than 10 cases of cetirizine-related acute hepatitis have 
been reported in the literature [10].
Given that the pathophysiology of the DILI mechanism 
is not yet known, a specific diagnostic test could not be 
performed. It is not clear weather reintroducing the suspect 
drug would reproduce the same liver damage.
Finally, the patient was advised to avoid both medications. 
For future prescriptions, including other antibiotics and 
antihistamines, we recommended monitoring liver function 
during administration and the following weeks.
Recurrent DILI caused by drugs with different chemical 
structures is very rare. To our knowledge this is the first case of 
recurrent DILI with 2 different drugs: amoxicillin–clavulanate 
and cetirizine.
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